苍白球前部脑深部电刺激治疗抽动秽语综合征:随机双盲对照试验
这项在法国8家运动障碍中心开展的随机双盲对照试验,纳入19例18-60岁严重难治性抽动秽语综合征患者,评估双侧苍白球前部脑深部电刺激(aGPi DBS)的疗效。结论认为3个月aGPi DBS不足以减轻抽动严重程度。
要点
- 3个月aGPi DBS与假刺激相比,YGTSS评分变化无显著差异。
- 13例患者发生15起严重不良事件,包括4例DBS硬件感染。
- 需更长周期和最优刺激参数研究aGPi DBS疗效。
核心结论
- 3个月苍白球前部脑深部电刺激不足以减轻抽动秽语综合征患者的抽动严重程度。
研究设计与样本
- 随机双盲对照试验,从法国8家运动障碍专科医院招募18-60岁严重难治性抽动秽语综合征患者。
- 患者植入双侧aGPi DBS电极,3个月后按1:1随机分配接受活性或假刺激3个月,随后开放标签活性刺激6个月。
- 共纳入19例患者,17例(89%)随机分配,16例完成盲法评估(活性组7例[44%],假刺激组9例[56%])。
主要发现
- 13例患者发生15起严重不良事件(刺激前退出3例,活性组6起,假刺激组6起),包括4例DBS硬件感染。
- 其他严重不良事件包括1例电极错位(活性组)、1例抑郁症状(活性组)、3例抽动严重程度和焦虑增加(假刺激组2例,活性组1例)。
临床怎么用
- 对于严重难治性抽动秽语综合征,3个月aGPi DBS不足以作为有效减轻抽动严重程度的常规选择。
- 临床决策需权衡DBS手术风险,尤其是硬件感染等严重不良事件。
- 更长疗程和最优刺激参数的aGPi DBS疗效仍需研究,不宜据此短期结果否定长期潜力。
局限性
- 样本量小(随机17例,完成盲法评估16例),可能影响统计效力。
- 双盲期仅3个月,无法评估长期疗效。
- 刺激参数设置为低于副作用阈值,可能非最优参数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Deep brain stimulation (DBS) has been proposed to treat patients with severe Tourette's syndrome, and open-label trials and two small double-blind trials have tested DBS of the posterior and the anterior internal globus pallidus (aGPi). We aimed to specifically assess the efficacy of aGPi DBS for severe Tourette's syndrome. METHODS: In this randomised, double-blind, controlled trial, we recruited patients aged 18-60 years with severe and medically refractory Tourette's syndrome from eight hospitals specialised in movement disorders in France. Enrolled patients received surgery to implant bilateral electrodes for aGPi DBS; 3 months later they were randomly assigned (1:1 ratio with a block size of eight; computer-generated pairwise randomisation according to order of enrolment) to receive either active or sham stimulation for the subsequent 3 months in a double-blind fashion. All patients then received open-label active stimulation for the subsequent 6 months. Patients and clinicians assessing outcomes were masked to treatment allocation; an unmasked clinician was responsible for stimulation parameter programming, with intensity set below the side-effect threshold. The primary endpoint was difference in Yale Global Tic Severity Scale (YGTSS) score between the beginning and end of the 3 month double-blind period, as assessed with a Mann-Whitney-Wilcoxon test in all randomly allocated patients who received active or sham stimulation during the double-blind period. We assessed safety in all patients who were enrolled and received surgery for aGPi DBS. This trial is registered with ClinicalTrials.gov, number NCT00478842. FINDINGS: Between Dec 6, 2007, and Dec 13, 2012, we enrolled 19 patients. We randomly assigned 17 (89%) patients, with 16 completing blinded assessments (seven [44%] in the active stimulation group and nine [56%] in the sham stimulation group). We noted no significant difference in YGTSS score change between the beginning and the end of the 3 month double-blind period between groups (active group median YGTSS score 68·5 [IQR 34·0 to 83·5] at the beginning and 62·5 [51·5 to 72·0] at the end, median change 1·1% [IQR -23·9 to 38·1]; sham group 73·0 [69·0 to 79·0] and 79·0 [59·0 to 81·5], median change 0·0% [-10·6 to 4·8]; p=0·39). 15 serious adverse events (three in patients who withdrew before stimulation and six each in the active and sham stimulation groups) occurred in 13 patients (three who withdrew before randomisation, four in the active group, and six in the sham group), with infections in DBS hardware in four patients (two who withdrew before randomisation, one in the sham stimulation group, and one in the active stimulation group). Other serious adverse events included one electrode misplacement (active stimulation group), one episode of depressive signs (active stimulation group), and three episodes of increased tic severity and anxiety (two in the sham stimulation group and one in the active stimulation group). INTERPRETATION: 3 months of aGPi DBS is insufficient to decrease tic severity for patients with Tourette's syndrome. Future research is needed to investigate the efficacy of aGPi DBS for patients over longer periods with optimal stimulation parameters and to identify potential predictors of the therapeutic response. FUNDING: French Ministry of Health.
引用
- Welter ML, Houeto JL, Thobois S, et al. Anterior pallidal deep brain stimulation for Tourette's syndrome: a randomised, double-blind, controlled trial. Lancet Neurol. 2017. PMID: 28645853. doi:10.1016/S1474-4422(17)30160-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。